Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center.

December 20, 2021 — Immunolight LLC, a clinical stage biopharmaceutical firm leading the way in advancing technologies to transform cancer treatment, announced today it is now recruiting patients for a phase 1 study of its X-PACT Cancer Treatment system in Breast, Melanoma, Sarcoma and Head and Neck Cancers, to be conducted at Duke University Medical Center

The heart of the X-PACT system is 8-MOP (also known as 8-methoxypsoralen or methoxsalen) which has been successfully used for decades in the treatment of autoimmune disease, skin disorders and certain skin and blood cancers. However, since UV light, which is needed to activate 8-MOP, cannot penetrate through tissue, it has not been possible to use 8-MOP to treat solid tumors.  Immunolight's X-PACT system solves this problem.  Innovative Immunolight phosphor materials convert tissue penetrating energies, such as low dose X-ray, into UV light inside solid tumors in the body.  These energy converting phosphors are injected along with 8-MOP into the solid tumor, and low dose x-ray energy is applied at the site.  The phosphors convert the x-ray into UV light which activates the 8-MOP inside the solid tumor to kill the cancer.

More details about the Phase 1 trial and eligibility criteria can be found here

Immunolight founder and CEO Rick Bourke commented, "We are thrilled to start patient recruitment and begin this Phase 1 trial, bringing our innovative technology to fruition in treating cancer and starting what we believe is a new era in cancer treatment."

This milestone is the culmination of over 13 years of intense research and development in partnership with Duke University and Duke Medical Center where a team of over 30 scientists, physicians and engineers has been active.  "From day one, our highest priority has been to translate this amazing science into a paradigm changing cancer treatment in patients," President Harold Walder said. "We are so excited to take this next step to get the treatment into the clinic." 

For more information: www.immunolight.com


Related Content

News | Radiation Therapy

May 14, 2025 — Siemens Healthineers is investing $150 million in new projects to expand production, create jobs and ...

Time May 15, 2025
arrow
News | Radiation Oncology

May 2, 2025 — GE HealthCare has announced an intended expansion of its radiation oncology portfolio as well as the ...

Time May 03, 2025
arrow
News | Radiology Education

April 21, 2025 — On June 20, the American Society of Radiologic Technologists (ASRT) will award Life Member status to ...

Time April 21, 2025
arrow
News | Radiology Business

April 16, 2025 — According to a new report, the U.S. Radiotherapy Market is projected to reach $2.49 billion by 2030 ...

Time April 17, 2025
arrow
News | ASTRO

March 14, 2025 — Another pivotal milestone in the nation’s fight against cancer recently took place with the ...

Time March 17, 2025
arrow
News | Computed Tomography (CT)

Royal Philips recently received 510(k) clearance from the US Food and Drug Administration (FDA) for its detector-based ...

Time November 13, 2024
arrow
News

Aug. 5, 2024 — Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that adding ...

Time August 09, 2024
arrow
News | Radiology Business

July 31, 2024 — The American Registry of Radiologic Technologists (ARRT) announced the three Registered Technologists (R ...

Time July 31, 2024
arrow
News | PET-CT

July 31, 2024 — In a head-to-head comparison with FDG PET/CT, FDG PET/MRI demonstrated comparable or superior diagnostic ...

Time July 31, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 30, 2024
arrow
Subscribe Now